|Bid||252.00 x 800|
|Ask||255.09 x 800|
|Day's Range||250.50 - 257.00|
|52 Week Range||207.33 - 276.69|
|Beta (5Y Monthly)||0.74|
|PE Ratio (TTM)||20.77|
|Earnings Date||Apr 28, 2021 - May 03, 2021|
|Forward Dividend & Yield||7.04 (2.75%)|
|Ex-Dividend Date||May 14, 2021|
|1y Target Est||255.93|
Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses.
Amgen has been in a long-term uptrend but the stock has been stalled for the past year. The indicators I favor are looking more positive so let's check out the charts to see if this is the time to buy.